CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 363 enrolled
Drug / intervention
sitagliptin phosphate +1 moredrug
Likely dose
Sitagliptin phosphate 25–200 mg orally once daily for 12 weeksAI-extracted
Key inclusion· 1
  • ✓Type 2 diabetes mellitus diagnosis
Key exclusion· 1
  • ✕Type 1 diabetes mellitus

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00127192
NCT00127192Phase 2Completed
CompareCT.gov

Sitagliptin (MK0431) Late Phase II Double-Blind Dose-Response Study - Type 2 Diabetes Mellitus

Merck Sharp & Dohme LLC·interventional·Posted Aug 5, 2005·Updated Jun 15, 2015

In Brief

A Phase 2 clinical trial evaluating sitagliptin phosphate and Comparator: placebo (unspecified) for Type 2 Diabetes Mellitus. Completed, enrolled 363 participants.

Detailed Summary

The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with type 2 diabetes mellitus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 5, 2005
Enrollment StartJul 1, 2005
Primary CompletionMar 1, 2006
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 20.9 years ago

Interventions

sitagliptin phosphatedrug

sitagliptin phosphate 25 mg, 50 mg, 100 mg QD, or 200 mg QD 12-weeks.

Comparator: placebo (unspecified)drug

placebo QD 12-weeks